Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Executive Summary
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
You may also be interested in...
Sanofi Catching Up To Market Growth Rates As Q3 Sales Rise Double Digits
Sanofi Consumer Healthcare's second successive quarter of growth means the business is now growing almost as fast as the global OTC market. Business head Julie Van Ongevalle has won praise from the French group's CEO Paul Hudson for driving a "quite extraordinary" transformation.
Sanofi To Divest 60% Of Brands In Consumer Healthcare Overhaul
Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.
Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch
Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.